A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer by M. S. Brose, Yu. Panaseykin, B. Konda, C. de la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor

Subjects: “…радиойодрефрактерный дифференцированный рак щитовидной железы…”
Get full text